Immuron Ltd 6-K, filed Mar 16, 2022
Immuron Ltd (IMRN)
About this 6-K
Immuron Ltd filed this 6-K on March 16, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of March 2022
Commission File Number: 001-38104
IMMURON LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South,Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
IMMURON LIMITED
EXPLANATORY NOTE
Immuron Limited (the “Company”) published one announcement (the “Public Notices”) to the Australian Securities Exchange on March 16, 2022 titled:
| - | “Appointment of Paul Brennan as Non-Executive Director” |
|---|
A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.
This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
EXHIBITS
| Exhibit<br><br>Number | Description |
|---|---|
| 99.1 | Appointment of Paul Brennan as Non-Executive Director |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IMMURON LIMITED | ||
|---|---|---|
| Date: March 16, 2022 | By: | /s/ Phillip Hains |
| Phillip Hains | ||
| Company Secretary |
2
Exhibit 99.1
ASX Announcement
Wed 16 March 2022
Appointmentof Paul Brennan as Non-Executive Director
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of Paul Brennan as an independent Non-Executive Director of the Company with effect from today.
Mr Brennan has extensive experience in the health system through his clinical background and commercial exposure with various multinational companies. Mr Brennan was Chief Executive Officer (CEO) of PolyNovo Limited (ASX:PNV) for 7 years from 2015 to 2021 and took the company from a market capitalisation of $30M to a high of $2B. Prior to this Mr Brennan was Marketing Director Australia and New Zealand and Sales Director New Zealand for Smith & Nephew Healthcare for 6 years.
Commenting on his appointment, Paul Brennan said, “Immuron has unique intellectual property that places it at the forefront of gut health. This emerging field of medical advancement,coupled with Immuron’s strength in clinical research, should deliver significant market opportunity. I am looking forward to workingclosely with the team.”
Dr. Roger Aston, Non-Executive Chairman, said, “we are delighted with the appointment of Paul to the Board as he brings a diverse background including commercialisationof technology, company governance, strategic planning and international marketing and more.”
This release has been authorised by the directors of Immuron Limited.
-
-
- END - - -
-
COMPANY CONTACT:
Dr Jerry Kanellos, Ph.D.
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com
| Level 3, 62 Lygon Street,<br><br><br><br>Carlton South, Victoria<br><br><br><br>AUSTRALIA 3053 | www.immuron.com<br><br><br><br>ABN: 80 063 114 045 | Phone: + 61 (0)3 9824 5254 |
|---|
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
About Travelan^®^
Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers’ diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.
About Travelers’ diarrhea
Travelers’ diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating and fever. Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused with travelers’ diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.
For more information visit: http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-lookingstatements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product developmentprograms and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectationsand are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stockvalue. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growthstrategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to theresults of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertaintiesrelating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain keypersonnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent andintellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligationor undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change inour expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.